Q-omics provides the consensus-scored SOX5 profile across patient tissues and cancer cell-line models. SOX5 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SOX5 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, SOX5 RNA expression shows 17,810 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, LUAD, and THYM as cancer lineages where SOX5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SOX5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SOX5 survival associations across molecular data types. SOX5 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SOX5 RNA expression–survival associations across cancer types. High SOX5 expression shows unfavorable associations in KIRP, LGG, STAD and LUAD, but favorable associations in KIRC and BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SOX5 RNA expression.
This table summarizes SOX5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SOX5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SOX5 shows lower tumor expression in LUAD, THCA, COAD, KIRC, BLCA and LUSC. The LUAD box plot shows higher SOX5 RNA expression in normal versus tumor tissue (log2 FC = −1.201, t-test p < 0.001).
This table shows molecular features associated with SOX5 in patient tissues and cancer cell lines. In patient samples, SOX5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SOX5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
